November 28, 2016 - By Adrian Mccoy · 0 Comments
The stock of Cellular Biomedicine Group Incorporated (NASDAQ:CBMG) registered an increase of 0.34% in short interest. CBMG’s total short interest was 412,000 shares in November as published by FINRA. Its up 0.34% from 410,600 shares, reported previously. With 12,500 shares average volume, it will take short sellers 33 days to cover their CBMG’s short positions. The short interest to Cellular Biomedicine Group Incorporated’s float is 4.87%. About 15,357 shares traded hands. Cellular Biomedicine Group Inc (NASDAQ:CBMG) has declined 22.57% since April 25, 2016 and is downtrending. It has underperformed by 28.58% the S&P500.
Cellular Biomedicine Group, Inc. is a biomedicine company. The company has a market cap of $209.71 million. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. It currently has negative earnings. The Firm operates in Biomedicine Cell Therapy segment.
Insitutional Activity: The institutional sentiment decreased to 2 in Q2 2016. Its down 2.17, from 4.17 in 2016Q1. The ratio fall, as 2 funds sold all Cellular Biomedicine Group Inc shares owned while 4 reduced positions. 6 funds bought stakes while 19 increased positions. They now own 2.46 million shares or 131.54% more from 1.06 million shares in 2016Q1.
New York State Common Retirement Fund holds 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 9,000 shares. American Int Group, a New York-based fund reported 7,000 shares. The New York-based Bancorp Of Ny Mellon has invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Legal & General Group Inc Public Limited Company holds 2,192 shares or 0% of its portfolio. Blackrock Fund Advsr accumulated 313,978 shares or 0% of the stock. Tower Rech Capital (Trc) owns 868 shares or 0% of their US portfolio. The New York-based Citigroup Inc has invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Goldman Sachs Group owns 18,703 shares or 0% of their US portfolio. Deutsche National Bank Ag has invested 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Morgan Stanley accumulated 0% or 50 shares. Blackrock Investment Management Ltd last reported 0% of its portfolio in the stock. Moreover, State Street Corp has 0% invested in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 114,909 shares. Schwab Charles Invest Mngmt Inc holds 0% or 22,709 shares in its portfolio. Wells Fargo Co Mn holds 0% or 4,785 shares in its portfolio. Blackrock Institutional Tru Na has invested 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG).
Cellular Biomedicine Group, Inc. (CBMG), incorporated on January 18, 2013, is a biomedicine company. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. The Firm operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Firm is focused on developing and marketing cell therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
More news for Cellular Biomedicine Group Inc (NASDAQ:CBMG) were recently published by: Globenewswire.com, which released: “Cellular Biomedicine Group Announces Dismissal of Class Action Litigation” on August 18, 2016. Globenewswire.com‘s article titled: “Cellular Biomedicine Group Announces Annual General Meeting of Stockholders” and published on August 01, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy